XNASALDX
Market cap284mUSD
Jan 16, Last price
4.78USD
1D
-4.88%
1Q
-16.14%
Jan 2017
-10.65%
IPO
-28.66%
Name
Aldeyra Therapeutics Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
22.14%
Rev. gr., 5y
%
Revenues
0k
Net income
-38m
L-38.83%
CFO
-30m
L-46.46%
Earnings
Mar 05, 2025
Profile
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | 43,057 | 62,939 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (43,057) | (62,939) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | (655) | ||||||||
Tax Rate | |||||||||
NOPAT | (43,057) | (62,283) | |||||||
Net income | (37,543) -38.83% | (61,369) 3.57% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | (228) | 1,123 | |||||||
BB yield | 0.11% | -0.28% | |||||||
| Debt | |||||||||
Debt current | 15,625 | 1,161 | |||||||
Long-term debt | 1,054 | 15,172 | |||||||
Deferred revenue | 6,000 | ||||||||
Other long-term liabilities | (272) | ||||||||
Net debt | (126,144) | (157,968) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (30,326) | (56,637) | |||||||
CAPEX | (16) | ||||||||
Cash from investing activities | 30,000 | (29,955) | |||||||
Cash from financing activities | (1,270) | 1,220 | |||||||
FCF | (43,305) | (62,168) | |||||||
| Balance | |||||||||
Cash | 142,823 | 174,301 | |||||||
Long term investments | |||||||||
Excess cash | 142,823 | 174,301 | |||||||
Stockholders' equity | (394,200) | (356,762) | |||||||
Invested Capital | 535,491 | 523,854 | |||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 58,943 | 58,406 | |||||||
Price | 3.51 -49.57% | 6.96 74.00% | |||||||
Market cap | 206,891 -49.11% | 406,505 88.05% | |||||||
EV | 80,747 | 248,538 | |||||||
EBITDA | (42,794) | (62,680) | |||||||
EV/EBITDA | |||||||||
Interest | 2,071 | 1,694 | |||||||
Interest/NOPBT | |||||||||